ストックスクリーナーアプリを入手
1.70
0.58%
-0.01
前日終値:
$1.71
開ける：
$1.7
24時間の取引高:
121.79K
Relative Volume:
0.22
時価総額：
$106.81M
収益：
$13.86M
当期純損益:
$-79.62M
株価収益率:
-1.3245
EPS:
-1.2835
ネットキャッシュフロー:
$-63.51M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+1.80%
6か月 パフォーマンス:
-49.25%
1年 パフォーマンス:
+82.03%
1日の値動き範囲:
$1.66
$1.72
1週間の範囲:
$1.60
$1.84
52週間の値動き範囲:
$0.92
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.70 | 107.44M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-11-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-08-08 | 開始されました | Stifel | Buy |
| 2024-05-07 | 再開されました | Jefferies | Buy |
| 2024-02-09 | 開始されました | BTIG Research | Buy |
| 2024-01-23 | 開始されました | Leerink Partners | Outperform |
| 2023-09-05 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-11-02 | 開始されました | BofA Securities | Neutral |
| 2021-11-02 | 開始されました | Credit Suisse | Outperform |
| 2021-11-02 | 開始されました | Jefferies | Buy |
すべてを表示
Pyxis Oncology Inc (PYXS) 最新ニュース
Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative
Growth Value: Will Pyxis Oncology Inc stock benefit from M ARate Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Stock Recap: Can Pyxis Oncology Inc benefit from deglobalization2026 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Price Action: Is Pyxis Oncology Inc part of any major index2026 Reactions & Low Drawdown Momentum Ideas - baoquankhu1.vn
Trade Report: Can Pyxis Oncology Inc expand its profit marginsCPI Data & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - marketbeat.com
PYXS Technical Analysis & Stock Price Forecast - Intellectia AI
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
HC Wainwright Raises Earnings Estimates for Pyxis Oncology - Defense World
Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
HC Wainwright Expects Increased Earnings for Pyxis Oncology - Defense World
Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia
Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan
Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com UK
Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - stocktitan.net
Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - stocktitan.net
Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan
[Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan
Director at Pyxis Oncology (PYXS) receives grant of 45,867 stock options - Stock Titan
Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares - MarketBeat
Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan
FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst - MarketBeat
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - marketbeat.com
Stifel cuts Pyxis Oncology stock price target on financing assumptions By Investing.com - Investing.com India
Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright - MarketBeat
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com India
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com - Investing.com India
H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target - Investing.com
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
RBC Capital Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5 - Moomoo
Stifel cuts Pyxis Oncology stock price target on financing assumptions - Investing.com
Pyxis Oncology Reports 2025 Financial Results, Advances MICVO Cancer Trials, and Announces New Leadership - Minichart
Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks
William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - Investing.com Canada
William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com UK
Jefferies raises Pyxis Oncology stock price target on drug data By Investing.com - Investing.com Australia
Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com
MicuRx Pharmaceuticals: Advancing Novel ADC Therapy MICVO for Difficult-to-Treat Head and Neck Cancer – Pipeline, Strategy, and Risks Overview - Minichart
Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Pyxis Oncology Inc (PYXS) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
0.77%
大文字化:
|
ボリューム (24 時間):